본문 바로가기

MHY2251, a New SIRT1 Inhibitor, Induces Apoptosis via JNK/p53 Pathway in HCT116 Human Colorectal Cancer Cells

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2KCI Q2
저널
Biomolecules & Therapeutics31(1) · pp.73 · 2023
피인용
Web of Science 23Scopus 21KCI 1
FWCI (Scopus)
1.77
JCR IF
JCR 2022 3.7
ISSN
1976-9148

저자

  1. 강용정제1저자Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
  2. 권영훈Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
  3. 장정윤Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
  4. 이준호Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
  5. 이상권Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Mfg Pharm, Busan 46241, South Korea
  6. 박유진Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Mfg Pharm, Busan 46241, South Korea
  7. 문형룡Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Mfg Pharm, Busan 46241, South Korea
  8. 정해영Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea
  9. 김남득교신저자Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Dept Pharm, Busan 46241, South Korea

초록

Sirtuins (SIRTs) belong to the nicotinamide adenine dinucleotide (NAD+)-dependent class III histone deacetylase family. They are key regulators of cellular and physiological processes, such as cell survival, senescence, differentiation, DNA damage and stress response, cellular metabolism, and aging. SIRTs also influence carcinogenesis, making them potential targets for anticancer therapeutic strategies. In this study, we investigated the anticancer properties and underlying molecular mechanisms of a novel SIRT1 inhibitor, MHY2251, in human colorectal cancer (CRC) cells. MHY2251 reduced the viability of various human CRC cell lines, especially those with wild-type TP53. MHY2251 inhibited SIRT1 activity and SIRT1/2 protein expression, while promoting p53 acetylation, which is a target of SIRT1 in HCT116 cells. MHY2251 treatment triggered apoptosis in HCT116 cells. It increased the percentage of late apoptotic cells and the sub-G1 fraction (as detected by flow cytometric analysis) and induced DNA fragmentation. In addition, MHY2251 upregulated the expression of FasL and Fas, altered the ratio of Bax/Bcl-2, downregulated the levels of pro-caspase-8, -9, and -3 proteins, and induced subsequent poly(ADP-ribose) polymerase cleavage. The induction of apoptosis by MHY2251 was related to the activation of the caspase cascade, which was significantly attenuated by pre-treatment with ZVAD-FMK, a pan-caspase inhibitor. Furthermore, MHY2251 stimulated the phosphorylation of c-Jun N-terminal kinase (JNK), and MHY2251-triggered apoptosis was blocked by pre-treatment with SP600125, a JNK inhibitor. This finding indicated the specific involvement of JNK in MHY2251-induced apoptosis. MHY2251 shows considerable potential as a therapeutic agent for targeting human CRC via the inhibition of SIRT1 and activation of JNK/p53 pathway.

키워드

MHY2251SIRT1JNKp53 pathwayApoptosisColorectal cancer cellHDAC INHIBITORSP53ACTIVATIONAUTOPHAGYINDUCTIONFUCOIDANFAMILYMAPK

식별자

Scopus EID
2-s2.0-85145054567
WoS UID
000825374200001
KCI
ART002909756